Metformin treatment after the hypoxia-ischemia attenuates brain injury in newborn rats

Mingchu Fang; Huai Jiang; Lixia Ye; Chenchen Cai; Yingying Hu; Shulin Pan; Peijun Li; Jian Xiao; Zhenlang Lin

doi:10.18632/oncotarget.20779

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Metformin treatment after the hypoxia-ischemia attenuates brain injury in newborn rats

Mingchu Fang, Huai Jiang, Lixia Ye, Chenchen Cai, Yingying Hu, Shulin Pan, Peijun Li, Jian Xiao _ and Zhenlang Lin

PDF | HTML | How to cite

Oncotarget. 2017; 8:75308-75325. https://doi.org/10.18632/oncotarget.20779

Metrics: PDF 1471 views | HTML 3608 views | ?

Abstract

Mingchu Fang1, Huai Jiang1, Lixia Ye1, Chenchen Cai1, Yingying Hu1, Shulin Pan1, Peijun Li2, Jian Xiao3 and Zhenlang Lin1

1Department of Neonatology, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China

2Center for Neuroscience Research, Children’s National Health System, Washington, DC 20010, United States

3Molecular Pharmacology Research Center, School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China

Correspondence to:

Jian Xiao, email: [email protected]

Zhenlang Lin, email: [email protected]

Keywords: metformin, neonatal hypoxic-ischemic brain injury, neuronal apoptosis, neuroinflammation, blood-brain barrier

Received: June 27, 2017 Accepted: July 30, 2017 Published: September 08, 2017

ABSTRACT

Neonatal hypoxic-ischemic (HI) brain injury is a devastating disease that often leads to death and detrimental neurological deficits. The present study was designed to evaluate the ability of metformin to provide neuroprotection in a model of neonatal hypoxic-ischemic brain injury and to study the associated molecular mechanisms behind these protective effects. Here, we found that metformin treatment remarkably attenuated brain infarct volumes and brain edema at 24 h after HI injury, and the neuroprotection of metformin was associated with inhibition of neuronal apoptosis, suppression of the neuroinflammation and amelioration of the blood brain barrier breakdown. Additionally, metformin treatment conferred long-term protective against brain damage at 7 d after HI injury. Our study indicates that metformin treatment protects against neonatal hypoxic-ischemic brain injury and thus has potential as a therapy for this disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20779

Publication Alerts

Research Papers:

Metformin treatment after the hypoxia-ischemia attenuates brain injury in newborn rats

Abstract